Table 2:
Select Active Phase 2/3 Clinical Trials Evaluating Immunotherapy in Prostate Cancer
| Intervention | Intervention | Population | Phase | Study Identifier |
|---|---|---|---|---|
| Vaccine | PROSTVAC | Localized PC (active surveillance) |
II | NCT02326805 |
| PROSTVAC | Localized PC (neoadjuvant) | II | NCT02153918 | |
| PROSTVAC | mCRPC | III | NCT01322490 | |
| pTVG-HP +/− GM-CSF | BRPC | II | NCT01341652 | |
| Vaccine + Hormonal Therapy | Enzalutamide +/− PROSTVAC | mCRPC | II | NCT01867333 |
| Ipilimumab + degarelix | mCSPC | II | NCT02020070 | |
| Ipilimumab + ADT | mCSPC | II | NCT01377389 | |
| DC1 vaccine + ADT | BRPC | II | NCT00970203 | |
| Vaccine + Radiation | AdV-tk + valacyclovir | Localized PC | III | NCT01436968 |
| Sipuleucel-T +/− radiation | mCRPC | II | NCT01807065 | |
| Sipuleucel + radiation | mCRPC | II | NCT02232230 | |
| Sipuleucel-T + SABR | mCRPC | II | NCT01818986 | |
| Sipuleucel-T +/− radium-223 | mCRPC | II | NCT02463799 | |
| Vaccine + Chemotherapy | DCVAC/PCa + docetaxel/prednisone | mCRPC | III | NCT02111577 |
| PROSTVAC + docetaxel | mCSPC | II | NCT02649855 | |
| Combination Immunotherapy | Sipuleucel-T, CT-011 (anti-PD1), cyclophosphamide | mCRPC | II | NCT01420965 |
| Sipuleucel-T + ipilimumab | mCRPC | II | NCT01804465 | |
| Sipuleucel-T + CYT107. (Interleukin-7) | mCRPC | II | NCT01881867 | |
| PROSTVAC +/− ipilimumab | Localized PC (neoadjuvant) | II | NCT02506114 | |
| pTVG-HP + pembrolizumab | mCRPC | I/II | NCT02499835 | |
| pTVG-HP + sipuleucel-T | mCRPC | II | NCT01706458 | |
| Nivolumab + ipilimumab | mCRPC | II | NCT02601014 | |
| Adenovirus (AdC68), plasmid DNA, tremelimumab, sunitinib | BRPC, mCRPC | I | NCT02616185 |
*
PC=prostate cancer; BRPC=biochemically recurrent prostate cancer; mCSPC=metastatic castration-sensitive prostate cancer